Weight-Loss combo CagriSema tested for drug interactions
NCT ID NCT06289504
First seen May 19, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This completed Phase 1 study in 34 adults with overweight or obesity examined whether CagriSema (a combination of cagrilintide and semaglutide) changes how the body processes atorvastatin (a cholesterol drug) and warfarin (a blood thinner). Participants took single doses of atorvastatin and warfarin before and after reaching steady-state levels of CagriSema. The goal was to measure drug levels in the blood and the effect of warfarin, helping guide safe co-prescribing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Altasciences Company Inc.
Montreal, Quebec, H3P 3P1, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CagriSema (cagrilintide and semaglutide combination)
What this could lead to
If successful, this study could help doctors understand how to safely prescribe common medications like atorvastatin and warfarin alongside CagriSema for weight management.
What could go wrong
This is a small, early-stage drug interaction study, not a test of weight loss or safety. Results may not apply to broader populations or predict real-world outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.